At the core of a successful drug discovery is a high-quality chemical library. A fit-for-purpose drug discovery library is not a random collection of compounds, but a collection of carefully curated chemistry that is designed to cover the diversity of drug-like chemistry space, and provide tractable starting points for medicinal chemistry optimisation.
This project will build on a national framework to provide Australian drug discovery organisations access to a comprehensive Hit ID platform that includes:
- a fit for purpose drug discovery library (up to 300,000 compounds);
- an ultra-high throughput screening facility;
- fragment-based drug design capability;
- a state of the art software platform for in silico drug discovery.
- New storage infrastructure and 310,000 compound bank to allow fast screening of compounds to determine new target drug formulations.
- 6 screenings have already been performed since the project completion.
Visit Cancer Therapeutics CRC for more details.
LinkedIn: Cancer Therapeutics CRC
|Consortium lead|| |
Cancer Therapeutics CRC Pty Ltd (CTx)
|Consortium members|| |
UniQuest, Walter and Eliza Hall Institute (WEHI), Children's Cancer Institute (CCI), Griffith University / Compounds Australia
|Project duration||August 2017 - June 2019 (Completed)|
|Contact||Brendon Monahan, Cancer CRC - email@example.com|